Screening for prostate cancer decreases the risk of metastatic disease at 12 years follow up.

In an article by Shroder et al published in Europe Urol (2012), the authors publish results from the European randomised study of screening for prostate cancer. They report that screening significantly reduces the risk of developing metastatic disease in the 76813 men with available data. At 12 years follow up 256 screened men and 410 control men had developed metastasis. This was a relative risk reduction of 30% or 3.1 per 1000 men randomised (42% in the intention to screen analysis).

Screening for prostate cancer using the PSA blood test remains amongst the most controversial subject in Urology, but this data adds significantly to the body of evidence supporting screening.